Matt Pauls
-
FDA Denies Langhorne-Based Savara Application for Rare Lung Disease Treatment
The Food and Drug Administration has rejected an application filed by Langhorne-based Savara for its new drug candidate Molbreevi as a treatment for rare lung…
Founding Partners
Advertisement
Affiliate Partners
